The company, which holds a portfolio of over 270 patents for fibroblast-based therapies, expects the transaction to close on or about June 29, 2026. Under the terms of the agreement, investors will receive 4,081,633 shares—or pre-funded warrants—alongside series A and series B warrants. These warrants carry an exercise price of $0.735 and will become active following necessary stockholder approval regarding the underlying stock issuance.

H.C. Wainwright & Co. is serving as the exclusive placement agent for the offering. While the firm anticipates an initial cash injection of $3 million, the total potential proceeds remain contingent on future warrant exercise, which is not guaranteed. FibroBiologics plans to allocate the net funds toward working capital and general corporate operations as it continues to develop its pipeline for chronic diseases, including multiple sclerosis and disc degeneration.